Eupraxia Pharmaceuticals Inc.

TSX:EPRX Stock Report

Market Cap: CA$163.9m

Eupraxia Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Eupraxia Pharmaceuticals's earnings have been declining at an average annual rate of -34.5%, while the Biotechs industry saw earnings growing at 19.3% annually.

Key information

-34.5%

Earnings growth rate

-1.5%

EPS growth rate

Biotechs Industry Growth51.1%
Revenue growth raten/a
Return on equity-361.2%
Net Marginn/a
Last Earnings Update30 Sep 2024

Recent past performance updates

No updates

Recent updates

Health Check: How Prudently Does Eupraxia Pharmaceuticals (TSE:EPRX) Use Debt?

Jul 30
Health Check: How Prudently Does Eupraxia Pharmaceuticals (TSE:EPRX) Use Debt?

Revenue & Expenses Breakdown

How Eupraxia Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TSX:EPRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-281022
30 Jun 240-27923
31 Mar 240-30922
31 Dec 230-28721
30 Sep 230-26717
30 Jun 230-24515
31 Mar 230-20414
31 Dec 220-18414
30 Sep 220-1459
30 Jun 220-14410
31 Mar 220-1459
31 Dec 210-1968
30 Sep 210-1536
30 Jun 210-1253
31 Mar 210-941
31 Dec 200-311
30 Sep 200-310
31 Dec 190-622
31 Dec 180-1045

Quality Earnings: EPRX is currently unprofitable.

Growing Profit Margin: EPRX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: EPRX is unprofitable, and losses have increased over the past 5 years at a rate of 34.5% per year.

Accelerating Growth: Unable to compare EPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: EPRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).


Return on Equity

High ROE: EPRX has a negative Return on Equity (-361.24%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies